Sudafed capsules sent abroad
Executive Summary
Burroughs Wellcome has been granted permission by a Washington State federal judge to export Sudafed capsules that were not in distribution at the time the product was recalled in March following two deaths from cyanide poisoning ("The Pink Sheet" March 11, p. 14). Approximately 28 mil. bulk capsules will be distributed by international Wellcome subsidiaries, which still market the capsules outside the U.S. About 350,000 boxes of packaged Sudafed capsules will be donated to relief organizations outside the U.S. The 1.8 mil. packages collected in the recall will be stored by the company until the FBI has completed its investigation into the tamperings. Burroughs Wellcome had asked if it could destroy the packages of recalled product for space considerations; that request was denied.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: